Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model. (Q46606593)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

title

Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Roberto Manservigi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

Anna Boero

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Rafaela Argnani

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Silvia Zucchini

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Vivì Miriagou

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Penelope Mavromara

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Michele Cilli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Maria Pia Grossi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Pier Giorgio Balboni

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Enzo Cassai

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

language of work or name

English

0 references

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

865-872

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15603886%20AND%20SRC:MED&resulttype=core&format=json

Herpes simplex virus infections

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Genital herpes: review of the epidemic and potential use of type-specific serology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

New developments in the epidemiology, natural history and management of genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Herpes simplex virus type 2 in the United States, 1976 to 1994.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Genital herpes simplex typing in genitourinary medicine: 1995-1999.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Underdiagnosis of Genital Herpes by Current Clinical and Viral-Isolation Procedures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Patients' perspectives on the burden of recurrent genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Risk Factors for the Sexual Transmission of Genital Herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

The acquisition of herpes simplex virus during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Medical care expenditures for genital herpes in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Prospects for control of herpes simplex virus disease through immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Herpes simplex viruses: is a vaccine tenable?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Recent progress in herpes simplex virus immunobiology and vaccine research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Herpesvirus entry: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Antibodies for the prevention and treatment of viral diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Effects of the passive transfer of anti-gB antibodies in a rabbit model of HSV-1-induced keratitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Red blood cells as delivery system for recombinant HSV-1 glycoprotein B: immunogenicity and protection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Local and systemic inoculation of DNA or protein gB1s-based vaccines induce a protective immunity against rabbit ocular HSV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Experimental keratitis in rabbits by human HSV-1 variants: prevention and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Mice genetic immunization with plasmid DNA encoding a secreted form of HSV-1 gB induces a protective immune response against herpes simplex virus type 1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

A prophylactic hepatitis B vaccine with a novel adjuvant system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Therapeutic vaccination against chronic viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Therapy experiences with herpes simplex antigen "Lupidon G"

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Expression of the herpes simplex virus type 1 glycoprotein E in human cells and in Escherichia coli: protection studies against lethal viral infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Development and evaluation of an ELISA using secreted recombinant glycoprotein B for determination of IgG antibody to herpes simplex virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Immunomodulatory effects of HSV2 glycoprotein D in HSV1 infected mice: implications for immunotherapy of recurrent HSV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025

inferred from DOI database lookup

7 January 2021

based on heuristic

Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.025